In the past decade, the FDA has approved 13 new agents and 29 treatments for multiple myeloma, which have transformed the treatment paradigm for patients. The expanded treatment options have resulted in significantly improved outcomes. Two decades ago, the median survival was approximately 3 years, and now it is 8 to 10 years and can be even longer for many patients. 

We are discussing the latest trends in multiple myeloma treatments and the next frontiers with Dr. Sikander Ailawadhi of Mayo Clinic, Anne Quinn Young of MMRF, Brian McMahon of SparkCures and Jennifer Ahlstrom of Myeloma Crowd Foundation.